INMUNE BIO INC. - COMMON STOCK

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

05 مايو 2025 06:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

16 أبريل 2025 06:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

14 أبريل 2025 07:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

01 أبريل 2025 06:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

27 مارس 2025 15:05:56 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

24 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

12 فبراير 2025 06:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

10 فبراير 2025 06:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

28 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

10 ديسمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

04 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

13 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

31 أكتوبر 2024 15:05:51 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

28 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

24 أكتوبر 2024 14:03:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

24 أكتوبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

11 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

30 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

26 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

17 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire